S Ramponi Selected Research

Anemia

2/2001

Decreased myelotoxicity of gemcitabine and cisplatin in advanced non-small cell lung cancer (NSCLC) with cisplatin infusion on day 15.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

S Ramponi Research Topics

Disease

3	Neoplasms (Cancer) 12/2021 - 01/2001
2	Breast Neoplasms (Breast Cancer) 09/2018 - 10/2016
2	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 02/2001 - 01/2001
1	Overweight 12/2021
1	Obesity 12/2021
1	Hyperglycemia 09/2018
1	Renal Cell Carcinoma (Grawitz Tumor) 09/2018
1	Neuroendocrine Tumors (Neuroendocrine Tumor) 09/2018
1	Neutropenia 02/2001
1	Vomiting 02/2001
1	Anemia 02/2001
1	Thrombocytopenia (Thrombopenia) 02/2001
1	Lung Neoplasms (Lung Cancer) 01/2001
1	Small Cell Lung Carcinoma (Small Cell Lung Cancer) 01/2001

Drug/Important Bio-Agent (IBA)

2	Everolimus FDA Link 09/2018 - 10/2016
1	LipidsIBA 09/2018
1	TOR Serine-Threonine KinasesIBA 09/2018
1	exemestane (Aromasin)FDA Link 10/2016
1	Gemcitabine FDA Link 02/2001
1	Cisplatin (Platino)FDA LinkGeneric 02/2001

Therapy/Procedure

2	Therapeutics 12/2021 - 01/2001
2	Drug Therapy (Chemotherapy) 09/2018 - 01/2001
1	Immunotherapy 12/2021
1	Molecular Targeted Therapy 09/2018
1	Transplantation 09/2018